Vytalyou: Doctor-led Longevity and Preventive Healthcare Startup Raises Rs 9 Crore
Vytalyou, a doctor-led startup focused on longevity and preventive healthcare, has successfully secured Rs 9 crore in a pre-Series A funding round. This round was supported by Chetan Jain from Pharma Dose and Ratan Jain from Venus Industries, resulting in a company valuation of approximately Rs 33 crore. The funds are earmarked for the expansion of Incremental Lifestyle Clinics throughout Mumbai, as stated in a recent press release.
Established in 2025 by Chirantan Bose and Preetesh Bhandari, Vytalyou delivers a range of preventive healthcare services with a strong emphasis on longevity. The startup integrates diagnostics with bespoke health interventions and medically supervised care. Vytalyou operates out of Mumbai, offering services that include pathology, radiology, cardio-respiratory evaluations, body composition assessments, cancer screening, genetic testing, gut microbiome analysis, personalised IV therapies, and regenerative treatments. Additionally, the company provides non-invasive pain management solutions specifically for chronic musculoskeletal conditions.
AI-Driven Predictive Longevity Evaluation
Vytalyou employs an AI-based algorithm for its Predictive Longevity Evaluation, which meticulously assesses an individual’s health profile, biological age, and possible health risks. The findings are then reviewed by medical professionals, who create a tailored care plan based on the assessment results.
Client Reach and Expansion Plans
According to the company, it has catered to nearly 1,000 clients since inauguration, with about half of them acquired via walk-ins while the remaining were referrals through satisfied clients. Vytalyou has ambitious plans to scale with 10 new locations set to launch across India in the upcoming years.
Market Context and Competitors
Vytalyou is operating within India’s burgeoning preventive healthcare and longevity market, which has attracted several other startups. Notable competitors include Biopeak, Cent, Elevate Now, and Decode Age, all of which have also received significant investment. Biopeak secured $2.7 million in follow-on funding earlier this year, while Cent, co-founded by Practo’s Shashank ND, acquired approximately $5 million for its AI-driven early-detection platform targeting cancer, cardiac, neurological, and metabolic disorders. Elevate Now raised Rs 18 crore in seed funding, and Decode Age gathered Rs 14.48 crore in a pre-Series A round to enhance its capabilities in longevity research, biomarker discovery, multi-omics, and microbiome studies.